SUNDAY, SEPTEMBER 25, 2016

Pfizer obtains herpes vaccine candidate from Redvax

Pfizer said on Monday that it recently acquired a controlling interest in Redvax GmbH, a spinoff from Redbiotec AG, a Swiss biopharmaceutical company.

The move will give Pfizer access to a preclinical human cytomegalovirus (CMV) vaccine candidate to treat herpes in addition to intellectual property and a technology platform related to a second undisclosed vaccine.

“We are working to bring innovative vaccines to market that prevent and treat serious diseases,” Pfizer Senior Vice President and CSO of Vaccine Research and Early Development Kathrin U. Jansen said. “Through the acquisition of the Redvax innovative CMV vaccine platform and expertise, we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”

The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately 5,000 children each year in the U.S. suffer from health problems caused by CMV, such as hearing loss, vision loss and mental disability. The Institute of Medicine has made the creation and development of a CMV vaccine a high priority due to the number of lives it would potentially save and the disabilities it may prevent. CMV expenses can run more than $300,000 per child a year, according to the CDC.

“We are pleased to have completed this deal with Pfizer, a global leader in vaccines,” Redvax Managing Director and Redbiotec CEO Christian Schaub said. “This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families. We believe that combining Redvax’s assets with Pfizer’s commitment, expertise and resources will significantly enhance the potential of developing this important vaccine.”

Organizations in this story

Pfizer 235 E 42nd St New York, NY 10017-5703

Get notified the next time we write about Pfizer!